Omaveloxolone is a treatment for Friedreich’s ataxia that has been developed by Reata Pharmaceuticals. The US FDA has now granted omaveloxolone orphan drug designation based on promising results from the company’s early-stage research.
What is omaveloxolone?
Omaveloxolone works by activating Nrf2, which is a signalling process within our cells that is important for producing antioxidants. Antioxidants help defend against oxidative stress, which can damage cells.
Research has shown that Nrf2 signalling is impacted in people with Friedreich’s ataxia, which may contribute to the cause of the disease. Omaveloxolone is thought to restore Nrf2 signalling, thereby reducing the effects of the disease.
What has research shown so far?
The first part of the Phase II trial looked at the safety and effectiveness of omaveloxolone. It found that the drug was effective in restoring Nrf2 function and that this was associated with improved neurological function in patients. The second part of this Phase II trial will begin in the second half of 2017.
What is orphan drug designation?